Gen-Probe Invests $50M in PacBio; Companies to Co-Develop Sequencing-Based Diagnostics

The tests will likely be based on PacBio's "version 2" technology, which is scheduled to launch in 2014, and could be applicable for point-of care diagnostics, a clinical laboratory, or a service center.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.